SCI Abstract

search
Book review on hypoxic respiratory failure in the  newborn – from origins to clinical management
Book review on hypoxic respiratory failure in the newborn – from origins to clinical management
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
2021 Annual World Congress of the Pulmonary  Vascular Research Institute Webinar Series
2021 Annual World Congress of the Pulmonary Vascular Research Institute Webinar Series
Access to society journal content varies across our titles. If you have access to a journal via a society or association ...
Bisoprolol and/or hyperoxic breathing do not reduce hyperventilation in pulmonary arterial hypertension patients
Bisoprolol and/or hyperoxic breathing do not reduce hyperventilation in pulmonary arterial hypertension patients
Hyperventilation is common in pulmonary arterial hypertension and may be related to autonomic imbalance. Patients underwen...
Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies
Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies
Pulmonary vasodilator therapy is still often an off-label treatment for pulmonary hypertension in children. The aim of thi...
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmona...
BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
Whether mutations in the BMPR2 gene may influence the response to PAH-specific therapies has not yet been investigated. In...
PeakPETCO2 combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
PeakPETCO2 combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
Cardiopulmonary exercise testing and pulmonary function test are important methods for detecting human cardio-pulmonary fu...
Vascular remodeling of the small pulmonary arteries and measures of vascular pruning on computed tomography
Vascular remodeling of the small pulmonary arteries and measures of vascular pruning on computed tomography
Pulmonary hypertension is characterized histologically by intimal and medial thickening in the small pulmonary arteries, e...
Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension
Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension
Alterations in metabolism and bioenergetics are hypothesized in the mechanisms leading to pulmonary vascular remodeling an...
A computational model of contributors to pulmonary hypertensive disease: impacts of whole lung and focal disease distributions
A computational model of contributors to pulmonary hypertensive disease: impacts of whole lung and focal disease distributions
Pulmonary hypertension has multiple etiologies and so can be difficult to diagnose, prognose, and treat. Diagnosis is typi...
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) are rapidly expanding. The purpose of this stu...
Systemic arterial properties in pulmonary hypertension
Systemic arterial properties in pulmonary hypertension
1. Galie, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hyperte...
Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb
Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb
Pharmacologic interventions to halt/reverse the vascular remodeling and right ventricular dysfunction in pulmonary arteria...
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Aberrant kinase signaling that involves platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 r...
Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary...
Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features
Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features
Sickle cell anemia and β-thalassemia intermedia are very different genetically determined hemoglobinopathies predisposing ...
Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicat...
Serious illness conversations in pulmonary hypertension
Serious illness conversations in pulmonary hypertension
Pulmonary arterial hypertension has evolved from a fatal disease with few treatment options to a chronic condition with im...
Liver abnormalities in pulmonary arterial hypertension
Liver abnormalities in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recog...
Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
Pulmonary arterial hypertension is an unmet clinical need. Imatinib, a tyrosine kinase inhibitor, 200 to 400 mg daily redu...
Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with ACVRL1 gene mutations
Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with ACVRL1 gene mutations
Pulmonary arterial hypertension is a kind of heart and lung vascular disease with low incidence and poor prognosis. Geneti...
Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hyperchol...